Phillip J Johnson
Overview
Explore the profile of Phillip J Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Palmer D, Johnson P
Cancer Metastasis Rev
. 2015 Aug;
34(3):497-509.
PMID: 26250585
Advanced hepatocellular carcinoma (aHCC) is a complex disease beset by underlying liver dysfunction and high molecular heterogeneity. Sorafenib, introduced in 2007, is considered the standard systemic therapy for aHCC, yet...
2.
Cairns D, Barrett J, Billingham L, Stanley A, Xinarianos G, Field J, et al.
Proteomics
. 2008 Dec;
9(1):74-86.
PMID: 19053145
Mass spectrometric profiling approaches such as MALDI-TOF and SELDI-TOF are increasingly being used in disease marker discovery, particularly in the lower molecular weight proteome. However, little consideration has been given...
3.
Ma B, Poon T, To K, Zee B, Mo F, Chan C, et al.
Head Neck
. 2003 Sep;
25(10):864-72.
PMID: 12966511
Background: This study prospectively examines the prognostic role of p53 oncoprotein (p53), Ki67-antigen (Ki67), tumor angiogenesis (MVD), epidermal growth factor receptor (EGFR), and HER2 receptor protein (HER2) expression in Chinese...
4.
Zhong S, Yeo W, Tang M, Wong N, Lai P, Johnson P
Clin Cancer Res
. 2003 Sep;
9(9):3376-82.
PMID: 12960125
Purpose And Experimental Design: The human Ras association domain family 1A gene (RASSF1A) is a newly isolated tumor suppressor gene. In this study, we analyzed the methylation status of the...
5.
Chow P, Tai B, Tan C, Machin D, Win K, Johnson P, et al.
Hepatology
. 2002 Oct;
36(5):1221-6.
PMID: 12395333
In the Asia-Pacific region and elsewhere, almost 85% of patients with hepatocellular carcinoma (HCC) are inoperable at diagnosis and have a dismal prognosis. Tamoxifen (TMX) is believed to inhibit HCC...